SymBio Pharmaceuticals Limited (TYO:4582)

Market Cap	5.14B
Revenue (ttm)	1.53B
Net Income (ttm)	-4.55B
Shares Out	55.82M
EPS (ttm)	-95.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	820,800
Average Volume	1,409,445
Open	91.00
Previous Close	94.00
Day's Range	90.00 - 92.00
52-Week Range	87.00 - 205.00
Beta	0.12
RSI	44.79
Earnings Date	Feb 5, 2026

About SymBio Pharmaceuticals

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and sales of pharmaceuticals and related operations to treat cancer, hematology, and viral infectious diseases in Japan and internationally. It offers SyB L-0501, an anti-cancer agent for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administration under the TREAKISYM name. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 108
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4582

Financial Performance

In 2024, SymBio Pharmaceuticals's revenue was 2.45 billion, a decrease of -56.13% compared to the previous year's 5.59 billion. Losses were -3.83 billion, 95.4% more than in 2023.